Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices.

Nascimbene A, Hernandez R, George JK, Parker A, Bergeron AL, Pradhan S, Vijayan KV, Civitello A, Simpson L, Nawrot M, Lee VV, Mallidi HR, Delgado RM, Dong JF, Frazier OH.

J Heart Lung Transplant. 2014 May;33(5):470-7. doi: 10.1016/j.healun.2014.01.004. Epub 2014 Jan 19.

2.

Macrovascular and microvascular function after implantation of left ventricular assist devices in end-stage heart failure: Role of microparticles.

Sansone R, Stanske B, Keymel S, Schuler D, Horn P, Saeed D, Boeken U, Westenfeld R, Lichtenberg A, Kelm M, Heiss C.

J Heart Lung Transplant. 2015 Jul;34(7):921-32. doi: 10.1016/j.healun.2015.03.004. Epub 2015 Mar 24.

PMID:
25980571
3.

Increased cyclic guanosine monophosphate levels and continuous-flow left-ventricular assist devices: Implications for gastrointestinal bleeding.

Grosman-Rimon L, Tumiati LC, Fuks A, Jacobs I, Lalonde SD, Cherney DZ, Rao V.

J Thorac Cardiovasc Surg. 2016 Jan;151(1):219-27. doi: 10.1016/j.jtcvs.2015.09.015. Epub 2015 Sep 18.

4.

Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients.

Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, Sundareswaran KS, Farrar DJ, Russell SD; HeartMate II Clinical Investigators.

J Am Coll Cardiol. 2014 Mar 11;63(9):880-8. doi: 10.1016/j.jacc.2013.08.1656. Epub 2013 Dec 11.

5.

Use of left ventricular assist device (HeartMate II): a Singapore experience.

Lim CP, Sivathasan C, Tan TE, Lim CH, Kerk KL, Sim DK.

Artif Organs. 2014 Jul;38(7):543-8. doi: 10.1111/aor.12247. Epub 2014 Jan 7.

PMID:
24392937
6.

Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.

John R, Pagani FD, Naka Y, Boyle A, Conte JV, Russell SD, Klodell CT, Milano CA, Rogers J, Farrar DJ, Frazier OH.

J Thorac Cardiovasc Surg. 2010 Jul;140(1):174-81. doi: 10.1016/j.jtcvs.2010.03.037. Epub 2010 May 5.

7.

Pre-Operative Right Ventricular Dysfunction Is Associated With Gastrointestinal Bleeding in Patients Supported With Continuous-Flow LeftĀ Ventricular Assist Devices.

Sparrow CT, Nassif ME, Raymer DS, Novak E, LaRue SJ, Schilling JD.

JACC Heart Fail. 2015 Dec;3(12):956-64. doi: 10.1016/j.jchf.2015.09.009. Epub 2015 Nov 11.

8.

Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump.

Goda M, Jacobs S, Rega F, Peerlinck K, Jacquemin M, Droogne W, Vanhaecke J, Van Cleemput J, Van den Bossche K, Meyns B.

J Heart Lung Transplant. 2013 May;32(5):539-45. doi: 10.1016/j.healun.2013.02.006.

PMID:
23570742
9.

The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.

Clegg AJ, Scott DA, Loveman E, Colquitt J, Hutchinson J, Royle P, Bryant J.

Health Technol Assess. 2005 Nov;9(45):1-132, iii-iv. Review.

10.

The impact of left ventricle assist device on circulating endothelial microparticles - pilot study.

Pitha J, Dorazilova Z, Melenovsky V, Kralova Lesna I, Stavek P, Stepankova J, Urban M, Maly J, Netuka I.

Neuro Endocrinol Lett. 2012;33 Suppl 2:68-72.

PMID:
23183513
11.

Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support).

Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, Russell SD, Conte JV, Aaronson KD, McGee EC Jr, Cotts WG, DeNofrio D, Pham DT, Farrar DJ, Pagani FD.

J Am Coll Cardiol. 2011 May 10;57(19):1890-8. doi: 10.1016/j.jacc.2010.10.062. Erratum in: J Am Coll Cardiol. 2011 Nov 8;58(20):2142.

12.

Outcome of cardiac transplantation in patients requiring prolonged continuous-flow left ventricular assist device support.

Takeda K, Takayama H, Kalesan B, Uriel N, Colombo PC, Jorde UP, Yuzefpolskaya M, Mancini DM, Naka Y.

J Heart Lung Transplant. 2015 Jan;34(1):89-99. doi: 10.1016/j.healun.2014.09.007. Epub 2014 Sep 8.

PMID:
25444372
13.

Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.

John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L.

Ann Thorac Surg. 2008 Oct;86(4):1227-34; discussion 1234-5. doi: 10.1016/j.athoracsur.2008.06.030.

PMID:
18805167
14.

Platelet glycoprotein IbĪ± ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices.

Hu J, Mondal NK, Sorensen EN, Cai L, Fang HB, Griffith BP, Wu ZJ.

J Heart Lung Transplant. 2014 Jan;33(1):71-9. doi: 10.1016/j.healun.2013.08.013. Epub 2013 Sep 19.

15.

Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support.

Petrucci RJ, Rogers JG, Blue L, Gallagher C, Russell SD, Dordunoo D, Jaski BE, Chillcott S, Sun B, Yanssens TL, Tatooles A, Koundakjian L, Farrar DJ, Slaughter MS.

J Heart Lung Transplant. 2012 Jan;31(1):27-36. doi: 10.1016/j.healun.2011.10.012.

PMID:
22153550
16.

Does continuous flow left ventricular assist device technology have a positive impact on outcome pretransplant and posttransplant?

Klotz S, Stypmann J, Welp H, Schmid C, Drees G, Rukosujew A, Scheld HH.

Ann Thorac Surg. 2006 Nov;82(5):1774-8.

PMID:
17062246
17.

Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation.

Sandner SE, Riebandt J, Haberl T, Mahr S, Rajek A, Schima H, Wieselthaler GM, Laufer G, Zimpfer D.

J Heart Lung Transplant. 2014 Jan;33(1):88-93. doi: 10.1016/j.healun.2013.10.009. Epub 2013 Oct 11.

PMID:
24239003
18.

Device exchange after primary left ventricular assist device implantation: indications and outcomes.

Stulak JM, Cowger J, Haft JW, Romano MA, Aaronson KD, Pagani FD.

Ann Thorac Surg. 2013 Apr;95(4):1262-7; discussion 1267-8. doi: 10.1016/j.athoracsur.2012.08.031. Epub 2012 Oct 11.

PMID:
23063192
19.

Clinical outcomes are similar in pulsatile and nonpulsatile left ventricular assist device recipients.

Feller ED, Sorensen EN, Haddad M, Pierson RN 3rd, Johnson FL, Brown JM, Griffith BP.

Ann Thorac Surg. 2007 Mar;83(3):1082-8.

PMID:
17307463
20.

Echocardiographic predictors of adverse outcomes after continuous left ventricular assist device implantation.

Topilsky Y, Oh JK, Shah DK, Boilson BA, Schirger JA, Kushwaha SS, Pereira NL, Park SJ.

JACC Cardiovasc Imaging. 2011 Mar;4(3):211-22. doi: 10.1016/j.jcmg.2010.10.012.

Supplemental Content

Support Center